Standard of care for glioma can yield inconclusive imaging results1,2
When complementing MRI results, certain amino acid PET tracers can provide full-color metabolic information about gliomas to improve clinical decisions.3,4
MRI, magnetic resonance imaging; NCCN, National Comprehensive Cancer Network; PET, positron emission tomography; RANO, Response Assessment in Neuro-Oncology.
References: 1. Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540-557. 2. Rosen J, Ceccon G, Bauer EK, et al. Cost effectiveness of 18F-FET PET for early treatment response assessment in glioma patients after adjuvant [generic Temodar] chemotherapy. J Nucl Med. 2022;63(11):1677-1682. 3. Smith NJ, Deaton TK, Territo W, et al. Hybrid 18F-fluoroethyltyrosine PET and MRI with perfusion to distinguish disease progression from treatment-related change in malignant brain tumors: the quest to beat the toughest cases. J Nucl Med. 2023;64(7):1087-1092. 4. Soni N, Ora M, Jena A, et al. Amino acid tracer PET MRI in glioma management: what a neuroradiologist needs to know. AJNR Am J Neuroradiol. 2023;44(3):236-246.
